Esmya Review Held Back Gedeon Richter in First Half

02 Aug 2018

• By John Davis

Sales of the uterine fibroid therapy, Esmya, sharply declined during the first half of 2018 at Hungary's specialty pharmaceuticals company, but an EU review of a potential association between the drug and liver injury has now been completed.

Budapest, the location of Gedeon Richter's HQ. • Source: Shutterstock

Temporary measures put in place while Gedeon Richter PLC's Esmya (ulipristal acetate) was reviewed by the EU's pharmacovigilance committee was one of two factors holding back the Hungarian company's sales growth during the first half of 2018. However, the review process for Esmya was completed on July 30, and has "opened the way for the relaunch of this product," the company says.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

30 Apr 2025

• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

30 Apr 2025

• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

29 Apr 2025

• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

AbbVie Increases US Manufacturing, But Says It’s Not Because Of Tariffs

25 Apr 2025

• By Joseph Haas

CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.